Open AccessWorkshop on Treatment of and Postexposure Prophylaxis forBurkholderia pseudomalleiandB. malleiInfection, 2010
Author(s) -
Rebecca Lipsitz,
Susan Garges,
Rosemarie Aurigemma,
Prasith Baccam,
David D. Blaney,
Allen Cheng,
Bart J. Currie,
David A. B. Dance,
Jay E. Gee,
Joseph Larsen,
Direk Limmathurotsakul,
Meredith G. Morrow,
Robert Norton,
Elizabeth O’Mara,
Sharon J. Peacock,
Nicki Pesik,
L. Paige Rogers,
Herbert P. Schweizer,
Ivo Steinmetz,
Gladys Tan,
Patrick Tan,
W. Joost Wiersinga,
Vanaporn Wuthiekanun,
Theresa Smith
Publication year - 2012
Publication title -
emerging infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.54
H-Index - 226
eISSN - 1080-6059
pISSN - 1080-6040
DOI - 10.3201/eid1812.120638
Subject(s) - burkholderia pseudomallei , microbiology and biotechnology , melioidosis , virology , burkholderia , medicine , biology , bacteria , genetics
The US Public Health Emergency Medical Countermeasures Enterprise convened subject matter experts at the 2010 HHS Burkholderia Workshop to develop consensus recommendations for postexposure prophylaxis against and treatment for Burkholderia pseudomallei and B. mallei infections, which cause melioidosis and glanders, respectively. Drugs recommended by consensus of the participants are ceftazidime or meropenem for initial intensive therapy, and trimethoprim/sulfamethoxazole or amoxicillin/clavulanic acid for eradication therapy. For postexposure prophylaxis, recommended drugs are trimethoprim/sulfamethoxazole or co-amoxiclav. To improve the timely diagnosis of melioidosis and glanders, further development and wide distribution of rapid diagnostic assays were also recommended. Standardized animal models and B. pseudomallei strains are needed for further development of therapeutic options. Training for laboratory technicians and physicians would facilitate better diagnosis and treatment option